文献速递心血管PETCT

左心室18F-氟比他班摄取在系统性轻链淀粉样变性中的预后价值

Prognostic Value of Left Ventricular 18F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis.
PubMed 文献 · JACC Cardiovasc Imaging · 2024-07-10

本研究纳入81例新诊断系统性轻链淀粉样变性患者,行18F-氟比他班PET/CT定量左心室淀粉样负荷(以注射剂量百分比表示)。左心室淀粉样负荷与12个月内主要不良心脏事件相关(HR 1.46,95%CI 1.16-1.83,P=0.001),但校正Mayo分期后该关联不再显著;中介分析提示该关联主要由NT-proBNP介导。

要点

  • 左心室18F-氟比他班摄取以注射剂量百分比定量淀粉样负荷,随负荷三分位升高,12个月内主要不良心脏事件发生率从7%升至63%(P<0.001)。
  • 左心室淀粉样负荷与主要不良心脏事件相关(HR 1.46,95%CI 1.16-1.83,P=0.001),但校正Mayo分期后不再显著。
  • 左心室淀粉样负荷与主要不良心脏事件的关联主要由NT-proBNP介导(P<0.001)。

核心结论

  • 左心室18F-氟比他班摄取以注射剂量百分比定量的淀粉样负荷可预测系统性轻链淀粉样变性患者12个月内主要不良心脏事件,但该效应不独立于Mayo分期,且主要由NT-proBNP介导。

研究设计与样本

  • 研究纳入81例新诊断系统性轻链淀粉样变性患者,行18F-氟比他班PET/CT成像,以注射剂量百分比定量左心室淀粉样负荷,Mayo分期依据肌钙蛋白T、N末端B型利钠肽原及游离轻链水平确定,主要不良心脏事件定义为12个月内全因死亡、心力衰竭住院或心脏移植。

诊断标准与关键数值

  • 主要不良心脏事件定义为12个月内全因死亡、心力衰竭住院或心脏移植;左心室淀粉样负荷以18F-氟比他班左心室摄取占注射剂量百分比定量;Mayo分期依据肌钙蛋白T、N末端B型利钠肽原及游离轻链水平确定。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Positron emission tomography/computed tomography (PET/CT) with 18F-florbetapir, a novel amyloid-targeting radiotracer, can quantify left ventricular (LV) amyloid burden in systemic light-chain (AL) amyloidosis. However, its prognostic value is not known.

OBJECTIVES: The authors' aim was to evaluate the prognostic value of LV amyloid burden quantified by 18F-florbetapir PET/CT, and to identify mechanistic pathways mediating its association with outcomes.

METHODS: A total of 81 participants with newly diagnosed AL amyloidosis underwent 18F-florbetapir PET/CT imaging. Amyloid burden was quantified using 18F-florbetapir LV uptake as percent injected dose. The Mayo stage for AL amyloidosis was determined using troponin T, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and free light chain levels. Major adverse cardiac events (MACE) were defined as all-cause death, heart failure hospitalization, or cardiac transplantation within 12 months.

RESULTS: Among participants (median age, 61 years; 57% males), 36% experienced MACE, increasing from 7% to 63% across tertiles of LV amyloid burden (P < 0.001). LV amyloid burden was associated with MACE (HR: 1.46; 95% CI: 1.16-1.83; P = 0.001). However, this association became nonsignificant when adjusted for Mayo stage. In mediation analysis, the association between LV amyloid burden and MACE was mediated by NT-proBNP (P < 0.001), a marker of cardiomyocyte stretch and heart failure, and a component of Mayo stage.

CONCLUSIONS: In this first study to link cardiac 18F-florbetapir uptake to subsequent outcomes, LV amyloid burden estimated by percent injected dose predicted MACE in AL amyloidosis. This effect was not independent of Mayo stage and was mediated primarily through NT-proBNP. These findings provide novel insights into the mechanism linking myocardial amyloid deposits to MACE.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Clerc OF, Datar Y, Cuddy SAM, et al. Prognostic Value of Left Ventricular 18F-Florbetapir Uptake in Systemic Light-Chain Amyloidosis. JACC Cardiovasc Imaging. 2024. PMID: 39001731. doi:10.1016/j.jcmg.2024.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。